Mara L. Becker, MD, MSCE, discusses how important it is to effectively treat juvenile idiopathic arthritis at an early stage to improve long-term outcomes in adulthood.
Search results for: juvenile idiopathic arthritis
FDA Approves Tofacitinib for Young Patients with Active Polyarticular JIA
Tofacitinib is now FDA approved to treat patients 2 years and older with active, polyarticular juvenile idiopathic arthritis.
Adalimumab for JIA-Associated Uveitis: 5-Year Follow-up
A five-year study in patients with juvenile idiopathic arthritis-associated uveitis found drug-induced disease remission did not persist once adalimumab was stopped after long-term treatment.
What Do JIA Patients Experience? A New Case Study from the ARP Practice Committee
What does a new patient experience as symptoms develop and diagnosis is confirmed? The ARP Practice Committee is developing persona-based case studies to help answer this and other questions. The latest topic is juvenile idiopathic arthritis…
Long-Term Canakinumab Treatment Has Favorable Effect on Systemic Features & Joint Health for sJIA
During a five-year trial of canakinumab, patients with systemic juvenile idiopathic arthritis taking canakinumab showed progress toward clinical remission and glucocorticoid tapering…
FDA Approves Subcutaneous Tocilizumab for Ages 2–17
The FDA has approved subcutaneous tocilizumab for treating active systemic juvenile idiopathic arthritis in pediatric patients as young as 2 years old…
Adalimumab + Methotrexate Effective for Uveitis in JIA
Research has found that taking adalimumab plus methotrexate is effective for patients with juvenile idiopathic arthritis-associated uveitis. However, these patients may also experience an increased incidence of adverse and serious adverse events compared with those taking only methotrexate…
Tocilizumab Promising for sJIA
In a clinical trial of pediatric patients, tocilizumab proved safe and effective for treating systemic juvenile idiopathic arthritis…
MicroRNA Mediates Gene Regulation That Underlies JIA Pathology
Through the use of large-scale transcriptome analysis, researchers have gained insight into the role of innate immunity in juvenile idiopathic arthritis (JIA) pathology. Specifically, transcriptomes of neutrophils in chronic inflammatory states demonstrate extensive network rewiring caused by microRNA, suggesting a role for alternative splicing in JIA pathogenesis…
The Genetic Factor: Research Examines Genetic Heritability for Pediatric Autoimmune Diseases
Recent research has helped further define genetic heritability for pediatric autoimmune diseases. In an interview, Dr. Hakon Hakanarson discusses how understanding common genetic factors can help develop risk prediction and treatments for such diseases as juvenile idiopathic arthritis, lupus and celiac disease…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 34
- Next Page »